⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

ImmuCell amends agreement with Norbrook Labs

EditorLina Guerrero
Published 02/12/2024, 22:26
ICCC
-

ImmuCell Corporation, a Maine-based company specializing in diagnostic substances for veterinary use with a market capitalization of $37.13 million, has amended its existing agreement with Norbrook Laboratories Limited. The amendment, effective as of November 29, 2024, modifies the Development Services and Commercial Supply Agreement initially established on September 5, 2019.

Under the original agreement, Norbrook Laboratories was responsible for providing formulation, aseptic filling, and packaging services for ImmuCell's product Re-Tain™, which is a treatment for subclinical mastitis in lactating dairy cows. This treatment is significant as it targets a condition that can affect milk production and quality in the dairy industry.

ImmuCell's stock, which is listed on the NASDAQ Capital Market under the ticker symbol ICCC, may see investor reaction to this updated agreement.

This news comes as part of ImmuCell's ongoing efforts to manage its product supply chain and partnerships, ensuring the continued availability and regulatory compliance of its veterinary health products. The company maintains a healthy liquidity position with a current ratio of 3.11, indicating strong ability to meet short-term obligations.

In other recent news, ImmuCell Corporation has reported a significant recovery in its Q3 2024 financial results, with gross margins improving to 26% and EBITDA turning positive. The company's First Defense product line saw an increase in sales of 11%, 51%, and 46% for the three, nine, and twelve months ending September 2024, respectively. Despite inflationary pressures and production yield losses, the company's cash position improved to approximately $3.8 million.

The FDA is currently reviewing ImmuCell's Re-Tain submission, which could potentially undergo an expedited review process. CEO Michael Brigham has discussed strategies to reduce the significant backlog and restore gross margins to the targeted 35%-40% range.

The company is also focused on reducing the backlog of orders, especially during the peak season from December to April. Lastly, ImmuCell is exploring strategic partnerships to support development expenses and working on the development of a new bulk feed powder product to reduce costs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.